Gliosarcoma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Gliosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

GlioblastomaGliosarcoma
Memorial Sloan Kettering Cancer Center60 enrolled9 locationsNCT06934889
Recruiting
Phase 1

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

GlioblastomaGlioblastoma MultiformeGliosarcoma
Baptist Health South Florida120 enrolled1 locationNCT05756985
Recruiting
Phase 1

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Recurrent Supratentorial GlioblastomaSupratentorial GliosarcomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center25 enrolled1 locationNCT04991870
Recruiting
Phase 1Phase 2

Study of Pembrolizumab and M032 (NSC 733972)

Glioblastoma MultiformeAnaplastic AstrocytomaGliosarcoma
University of Alabama at Birmingham28 enrolled1 locationNCT05084430
Recruiting
Phase 2

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaHigh Grade Astrocytic Tumor
Mayo Clinic54 enrolled1 locationNCT05465954
Recruiting
Phase 1Phase 2

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting
Phase 2

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Glioblastoma MultiformeGlioblastoma Multiforme, AdultSupratentorial Glioblastoma+1 more
Leland Metheny16 enrolled1 locationNCT05052957
Recruiting
Phase 1

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

GlioblastomaGliosarcoma
M.D. Anderson Cancer Center29 enrolled1 locationNCT04555577
Recruiting
Phase 2

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Glioblastoma MultiformeNewly Diagnosed GlioblastomaGlioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype+1 more
Northwestern University25 enrolled1 locationNCT05864534
Recruiting
Phase 1

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

GlioblastomaGliosarcoma, AdultGlioblastoma - Category
University College, London16 enrolled1 locationNCT07134842
Recruiting
Phase 1

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive+15 more
Florida International University65 enrolled1 locationNCT05857969
Recruiting

Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study

Glioblastoma, AdultGlioblastoma Multiforme, AdultGlioblastoma or Gliosarcoma
Sied Kebir128 enrolled2 locationsNCT06954636
Recruiting
Phase 1

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

GlioblastomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more
University of Nebraska24 enrolled1 locationNCT05698524